Source-backed half-life profile
Oxycodone half-life calculator
Oxycodone is a useful profile for seeing how a parent-drug curve can be much cleaner than the clinical questions people usually bring to it.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. The shaded band shows the reported half-life range. This is a mathematical visualization, not a personal concentration estimate.
What a careful reader should notice first
The half-life number helps with comparison, but formulation, metabolism, analgesia, and risk do not collapse into one percentage.
Source angle
Look for immediate-release versus extended-release context and whether sources discuss parent drug or metabolites.
Do not use it for
Do not use this page for dosing intervals, conversion, pain control, impairment, or safety timing.
Best next step
Compare with hydrocodone, morphine, and oxymorphone.
Oxycodone: evidence and interpretation notes
The plotted value belongs to immediate-release oxycodone
Immediate-release tablet labeling reports an apparent elimination half-life of 3.5 to 4 hours. HalfLifeDB uses the lower end of that small interval and identifies the formulation in the model label. An extended-release product may show a different apparent terminal profile because ongoing absorption changes the observed concentration-time curve.
Both tablet and solution labels describe the same parent compound, but they should not be used to erase formulation and absorption context. The normalized line starts after an abstract 100% point and therefore does not reproduce the rise to peak concentration for either product.
| Evidence source | What it contributes | Important limit |
|---|---|---|
| Immediate-release tablet labeling | The 3.5-to-4-hour apparent elimination range and metabolic pathways | Product labeling is not a prediction of analgesia or individual clearance |
| Oral-solution labeling | Cross-formulation context for immediate-release oxycodone | Solution absorption should not be assumed identical to every tablet product |
| Kinnunen clinical review | Special populations, routes, formulations, and interaction evidence | Broad clinical evidence cannot be collapsed into one correction factor |
| PubChem identity record | Compound identity | It does not support a formulation-specific half-life |
Metabolites do not turn this into a second opioid calculator
Oxycodone is metabolized through pathways that produce noroxycodone, oxymorphone, and noroxymorphone. Labeling identifies CYP3A-mediated formation of noroxycodone as the primary pathway, with a smaller CYP2D6 contribution to oxymorphone. The circulating amounts and pharmacological contribution of those metabolites are not represented by the parent line.
The Kinnunen review emphasizes that age, pregnancy, childhood, route, formulation, and enzyme-mediated interactions all create distinct pharmacokinetic questions. HalfLifeDB retains those as reading cautions rather than asking visitors for medical details and generating a personalized value.
Elimination is not analgesia or respiratory safety
A 3.5-hour curve is useful for comparing immediate-release parent oxycodone with longer or shorter reviewed profiles. It does not establish a dosing interval, duration of pain relief, conversion ratio, impairment window, or respiratory-risk timeline.
The correct reading is deliberately narrow: labeling supports a parent-drug apparent half-life around 3.5 to 4 hours for immediate-release products. Formulation, metabolism, repeated exposure, and patient context prevent that number from becoming a clinical clock.
Reading this curve
HalfLifeDB uses 3.5 h as a representative input for Immediate-release oxycodone. In the simplified model, about 0.9% remains after 24 hours and about 3% remains after five half-lives, or roughly 17.5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
opioid context
Opioid pharmacokinetics can differ between parent compounds and metabolites, and timing can vary by route, formulation, and individual clearance.
- Half-life is not a measure of respiratory risk or functional impairment.
- Active metabolites can matter even when the parent compound declines.
- Extended-release products require separate source context.
Oxycodone timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 30.5% | Long-tail portion of the model |
| 12 h | 9.29% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.86% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.01% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Oxycodone within the opioid group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Morphine (2 h)
Pharmacokinetics at a glance
| Representative half-life | 3.5 h |
|---|---|
| Modeled analyte or phase | Immediate-release oxycodone |
| Reported range | 3.5 h to 4 h |
| Curve type | Normalized, first-order decline |
Selection note: Immediate-release tablet labeling reports an apparent elimination half-life of 3.5 to 4 hours; the curve uses the lower end.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: Oxycodone hydrochloride tablet.Official immediate-release tablet labeling supporting the 3.5-to-4-hour apparent elimination range and metabolic pathways.
- Official labeling DailyMed label: Oxycodone hydrochloride solution.Official solution labeling included to compare immediate-release product context across formulations.
- Research abstract Kinnunen M et al. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone (2019).Clinical pharmacokinetics review covering special populations, alternate routes, formulations, and enzyme-mediated interactions.
- Identity record PubChem Compound Summary: Oxycodone.Compound identity record; background only.
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the opioid group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and profile review log before using the model for comparison.